A novel topical nano-propranolol for treatment of infantile hemangiomas
| Autor: | Ming Lu Yuan, Zheng Gang Chen, Wei En Yuan, Jia Wei Zheng, Ling Zhang |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Skin Neoplasms medicine.drug_class Administration Topical Adrenergic beta-Antagonists Biomedical Engineering Pharmaceutical Science Medicine (miscellaneous) Bioengineering Propranolol FAVORABLE RESPONSE Application site Infantile hemangioma medicine Humans General Materials Science Beta blocker Retrospective Studies Skin business.industry technology industry and agriculture Infant Mean age Hydrogels Surgery Nanostructures Tolerability Anesthesia Molecular Medicine Itching Female medicine.symptom Pharmaceutical Vehicles business Hemangioma medicine.drug |
| Zdroj: | Nanomedicine : nanotechnology, biology, and medicine. 11(5) |
| ISSN: | 1549-9642 |
| Popis: | Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH). A retrospective investigation was conducted in 50 patients to evaluate the clinical effect of a new type of topical nano-propranolol-dispersed hydrogel. Participants were treated 3 times per day for 2 weeks to 11 months. 68% of patients were female and 12% had received other treatments before therapy. The nano-propranolol 0.5% hydrogel was initiated at a mean age of 5.010 months and for a mean duration of 3.610 months. The response rate was 86%. No recurrence and rebound growth occurred after withdrawal of hydrogel. Slight side effects (application site itching, erosion and crusting) were observed in only 2 cases. All the local irritations were evaluated as mild and were tolerated without discontinuing the medication. We suggest that topical nano-propranolol hydrogel could be an alternative option for the treatment of uncomplicated superficial IH with satisfactory tolerability and optimal effectiveness. From the Clinical Editor The current recommended treatment for infantile hemangiomas is oral propranolol. Nonetheless, a small proportion of patients will have systemic side effects. In this article, the authors developed topical nano-propranolol hydrogel and tested this on clinical patients and found favorable response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect